Clinical Trials in Pittsburgh

Showing 1921-1940 of 10,050 trials

9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

NCT06896188

This is a study of the combination of 9 ING-41 (elraglusib) and retifanlimab plus mFOLFIRINOX in patients with pancreatic cancer without prior systemic therapy for advanced disease. The safety lead-in cohort will consist of 6 patients, followed by dose de-escalation if necessary, based on safety assessments. After evaluating the safety and tolerability at the initial dose level, the study will proceed to an expansion cohort at the determined safe dose level, with the total maximum enrollment not exceeding 12 patients for the entire study.

Pancreatic Adenocarcinoma

Anwaar Saeed12 participantsStarted Sep 2025

Pittsburgh, Pennsylvania, United States

Active Not Recruiting< 1 mile

A Registry for Participants With Chronic Hypoparathyroidism

NCT01922440

The main aim of this study is to find out the long-term safety and effectiveness profile of recombinant human parathyroid hormone (1-84) (rhPTH\[1-84\]) treatment in participants with chronic hypoparathyroidism under conditions of routine clinical practice. Participants will be treated according to their clinic's standard practice determined by the treating doctors. Each participant will fill out a study questionnaire during a routine doctor visit.

Hypoparathyroidism

Takeda1,339 participantsStarted Jul 2013

Birmingham, Alabama, United States • Tucson, Arizona, United States • Los Angeles, California, United States +97 more locations

9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

A Registry for Participants With Chronic Hypoparathyroidism

Find Trials by Condition in Pittsburgh

Diagnosis and Treatment of CAD in Severe PAD After Lower Extremity Revascularization

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Mobile Strategy to Reduce the Risk of Recurrent Preterm Birth

A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Performance of MOTO Medial® Unicompartmental Knee Arthroplasty

Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

SELUTION 4 De Novo Small Vessel IDE Trial

OP5-005 Using Omnipod 5 in Adults With Type 2

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Anti-viral Therapy in Alzheimer's Disease

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)